Search

ADMA Biologics Inc

Geschlossen

BrancheGesundheitswesen

9.84 0.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.69

Max

9.84

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.5M

38M

Verkäufe

9.9M

124M

KGV

Branchendurchschnitt

13.343

57.371

EPS

0.16

Gewinnspanne

30.405

Angestellte

640

EBITDA

-3.8M

57M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+72.76% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

66M

2.1B

Vorheriger Eröffnungskurs

9.02

Vorheriger Schlusskurs

9.84

Nachrichtenstimmung

By Acuity

50%

50%

150 / 340 Ranking in Healthcare

ADMA Biologics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 23:01 UTC

ADMA Biologics Inc shares declined in after-market trading, continuing a trend of lower finishes over the past three sessions amid broader market volatility.

20. Aug. 2026, 20:06 UTC

ADMA Biologics Inc shares are lower in Thursday's session, with no specific news identified. Broader market declines may be influencing sentiment amid rising Treasury yields.

19. Aug. 2026, 20:01 UTC

ADMA Biologics Inc shares are higher Wednesday, continuing a strong upward trend since Tuesday's close, despite no specific news driving the move.

17. Aug. 2026, 19:36 UTC

Correlated Moves
Social Media
News

ADMA Biologics is trading lower amid an investigation into potential fiduciary breaches by its Board of Directors. Broader market sentiment may also be impacting shares.

13. Aug. 2026, 20:02 UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

12. Aug. 2026, 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

11. Aug. 2026, 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

7. Aug. 2026, 19:46 UTC

Correlated Moves
News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

6. Aug. 2026, 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

5. Aug. 2026, 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

4. Aug. 2026, 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3. Aug. 2026, 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31. Juli 2026, 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30. Juli 2026, 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29. Juli 2026, 18:17 UTC

News
Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28. Juli 2026, 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27. Juli 2026, 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24. Juli 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22. Juli 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21. Juli 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20. Juli 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Peer-Vergleich

Kursveränderung

ADMA Biologics Inc Prognose

Kursziel

By TipRanks

72.76% Vorteil

12-Monats-Prognose

Durchschnitt 17 USD  72.76%

Hoch 21 USD

Tief 12 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ADMA Biologics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Stimmung

By Acuity

150 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
help-icon Live chat